Alfresa | Sustainability Performance
Operates a distribution network for pharmaceuticals, medical supplies, and healthcare products.
2003
Japan
10,001+ employees
Pharmaceuticals
$10B+ in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#1263
Overallⓘ#77
in Japanⓘ#36
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsEnergy consumptionSocial
Diversity and InclusionFinancial Data
Business performanceCapital & innovationAnalyst projections
Leading
Critical
Intensity
Energy consumption (direct) intensity (MWh /$M)
Industry Benchmark
16.8
B/M 42.0
Powered by illuminem and GIST Impact
Controversy level
- Alfresa Holdings Corporation, Japanese major pharmaceutical distributor (Alfresa, Tsumura affiliated), has faced sustained Japanese FTC enforcement scrutiny including the contested historic 20182019 USD 6.5 million Japanese FTC Akebono pharmaceutical wholesaler cartel investigation affecting Japanese institutional shareholders, plus periodic class actions over alleged inadequate disclosure of Japanese pharma distribution customer compliance affecting Japanese institutional shareholders.
